Technicals-
A clear base has formed and there is the first higher low after a significant trendline break (green circle).
There is also a bullish pattern on the 15 min within a 1hr bullish pattern where the peak of the 15 min pattern broke the final lower high of the 1hr pattern.
All these are very bullish signs.
Fundamentals -
GlucoTrack, Inc. (GCTK) is a medical technology company focused on developing non-invasive glucose monitoring devices, such as the GlucoTrack model DF-F, which uses ultrasound, electromagnetic, and thermal technologies to measure glucose levels without drawing blood.
Key Fundamentals:
Market Cap: $1.56 million
Employees: 61
Revenue: $0 (no recorded sales)
Net Income: -$14.91 million (loss)
Total Assets (Q3 2024): $826,000 (up 35.86% from Q2)
Total Liabilities: $4.85 million (up 24.40% from Q2)
Return on Equity (ROE): -1943.32%.
The company faces financial challenges with significant losses and liabilities exceeding assets. Its innovative technology targets a growing diabetes market but requires strong execution to improve financial health.
A clear base has formed and there is the first higher low after a significant trendline break (green circle).
There is also a bullish pattern on the 15 min within a 1hr bullish pattern where the peak of the 15 min pattern broke the final lower high of the 1hr pattern.
All these are very bullish signs.
Fundamentals -
GlucoTrack, Inc. (GCTK) is a medical technology company focused on developing non-invasive glucose monitoring devices, such as the GlucoTrack model DF-F, which uses ultrasound, electromagnetic, and thermal technologies to measure glucose levels without drawing blood.
Key Fundamentals:
Market Cap: $1.56 million
Employees: 61
Revenue: $0 (no recorded sales)
Net Income: -$14.91 million (loss)
Total Assets (Q3 2024): $826,000 (up 35.86% from Q2)
Total Liabilities: $4.85 million (up 24.40% from Q2)
Return on Equity (ROE): -1943.32%.
The company faces financial challenges with significant losses and liabilities exceeding assets. Its innovative technology targets a growing diabetes market but requires strong execution to improve financial health.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.